With the proliferation of diabetes around the globe, ophthalmologists located in countries that are treating diabetic retinopathy and diabetic macular edema (DME) more often now are in need of detailed guidelines to assist them.
People with Alzheimer’s disease are more likely to have drusen in their peripheral retinas, as well as unusual vascular characteristics, researchers believe.
Myopic traction maculopa (MTM) and macular hole retinal detachments (MHRDs) are complex scenarios that demand accurate diagnoses and high surgical expertise.
Editor’s Note: Ophthalmology Times is pleased to announce Peter H.
Elizabeth Atchison, MD, senior fellow, Rush University and Illinois Retina Associates Chicago, is the first-place honoree of the Ophthalmology Times Research Scholar Honoree Program. Below is her abstract:
The prevalence of visual impairment and blindness caused by diabetic retinopathy is increasing worldwide. Early recognition, perhaps via a screening programme, and timely management would be of benefit.
What's in a name? When it comes to ophthalmology, a lot. Persistent hyperplastic primary vitreous—an old name that addressees only the status of the primary vitreous—needs updating, said Michael Trese, MD.
Retina surgeons should learn a variety of techniques to treat proliferative diabetic retinopathy (PDR) so they can select which one to use on a case-by-case basis, recommended Andre V.
Throughout the body, any source of cellular damage (e.g., inflammation, infection, smoking, or high blood sugar) can liberate reactive oxygen species and set in motion an oxidative stress chain reaction that ultimately leads to tissue dam
First-line treatment for diabetic macular edema (DME) is overwhelmingly anti-vascular endothelial growth factor (VEGF) drugs, with more than two-thirds of clinicians around the world prescribing them for this patient population.